Super Session 1 - Why investing in early stage companies and innovative technologies?
Wednesday, September 14, 2016
•
S2
•
9:45 AM
>
10:45 AM
•
Super Session 1 - Why investing in early stage companies and innovative technologies?
•
Plenary Room A3
Co-Hosted by Lyfebulb & Sanofi
Access to capital is a prerequisite for start-ups developing new preventive measures or innovative treatments for patients. Venture capital may often be looking for later-stage opportunities, which forces young companies and emerging entrepreneurs to think creatively about financing sources. Non-dilutive disease foundations, government grants and venture philanthropy, may be options worthy of exploring as well as corporate venture arms and partnerships where capital is not the only asset. These models will be discussed and examples of companies, e.g. in the diabetic field benefiting from such funding, will be presented.
Moderator: Dr. Karin Hehenberger, Founder, Chairman and CEO, Lyfebulb
Speakers:
Dr. Ulrich Wendt, Head External Innovation & Alliance Management, Sanofi Diabetes, R&D
Mr. Part Chakrabarti, Senior Director, New Ventures & Transactions, J&J Innovation
Mr. John Sjöland, CEO and Co-Founder, Timesulin
Mr. Yngvar Berg, Director and Interim CEO, Algipharma
|